Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
American Journal of Hematology|February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myelomaSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Leukemia & Lymphoma|April 21, 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patientsSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of TherapyCyrille Touzeau, Roberto Mina, Hang Quach, et al.
The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
The Lancet. Oncology|September 16, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Lancet (London, England)|June 8, 2019
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyPhilippe Moreau, Michel Attal, Cyrille Hulin, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
American Journal of Hematology|February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myelomaSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Leukemia & Lymphoma|April 21, 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patientsSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of TherapyCyrille Touzeau, Roberto Mina, Hang Quach, et al.
The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
The Lancet. Oncology|September 16, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Lancet (London, England)|June 8, 2019
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyPhilippe Moreau, Michel Attal, Cyrille Hulin, et al.
Pageof 19